SCHEMBL10199991

SCHEMBL10199991

CC[C@@H](C=O)NC(=O)CN1C(=O)[C@@H](NC(=O)c2cccc3ccccc23)CN(C(=O)COC)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
XIAP P98170 19/20 0.46
CYP3A4 P08684 6/20 0.42
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL644733 0.93 CASP1 (0.50) XIAPCYP3A4CASP1
SCHEMBL10201335 0.85 CASP1 (0.52) XIAPCYP3A4CASP1
SCHEMBL10253189 0.83 XIAP (0.50) XIAPCYP3A4CASP1
SCHEMBL10263997 0.83 CASP1 (0.52) XIAPCYP3A4CASP1
SCHEMBL13139781 0.83 XIAP (0.46) XIAPCYP3A4CASP1
SCHEMBL10199304 0.82 CASP1 (0.53) XIAPCYP3A4CASP1
SCHEMBL13139761 0.82 CASP1 (0.45) XIAPCYP3A4CASP1
SCHEMBL13139786 0.82 XIAP (0.43) XIAPCYP3A4CASP1
SCHEMBL10268121 0.81 CASP1 (0.49) XIAPCYP3A4CASP1
SCHEMBL10284695 0.81 CASP1 (0.49) XIAPCYP3A4CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7790713-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-09-07 US disclosed
US-20080039449-A1 Inhibitors of interleukin-1beta converting enzyme BATCHELOR MARK J 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B XIAP 257/4885CYP3A4 2587/4885CASP1 6/4885
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B XIAP 257/4885CYP3A4 2587/4885CASP1 6/4885
US-20080039449-A1 Inhibitors of interleukin-1beta converting enzyme IL1A, IL1B, IFNAR1 XIAP 276/4885CYP3A4 2353/4885CASP1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.